Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas R Jones

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Expert Review of Vaccines|June 9, 2018
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccineJohn L Perez, Judith Absalon, Johannes Beeslaar, et al.
Vaccine|February 17, 2019
Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescentsTimo Vesikari, Lars Østergaard, Johannes Beeslaar, et al.
Vaccine|February 16, 2017
Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from FranceMuhamed-Kheir Taha, Julio Cesar Hawkins, Paul Liberator, et al.
Clinical and Vaccine Immunology : CVI|April 30, 2010
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlersSusanna Esposito, Susan Tansey, Allison Thompson, et al.
Infectious Diseases and Therapy|July 24, 2020
MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 StudiesJohannes Beeslaar, Judith Absalon, Annaliesa S Anderson, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2002
RFI-641, a potent respiratory syncytial virus inhibitorClayton C Huntley, William J Weiss, Anna Gazumyan, et al.
The Journal of Clinical Investigation|June 19, 2003
Heterologous immunity provides a potent barrier to transplantation toleranceAndrew B Adams, Matthew A Williams, Thomas R Jones, et al.
The Lancet. Infectious Diseases|October 18, 2016
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trialHelen S Marshall, Peter C Richmond, Johannes Beeslaar, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2004
Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survivalAndrew B Adams, Nozomu Shirasugi, Thomas R Jones, et al.
The Lancet. Infectious Diseases|May 10, 2012
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trialPeter C Richmond, Helen S Marshall, Michael D Nissen, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Expert Review of Vaccines|June 9, 2018
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccineJohn L Perez, Judith Absalon, Johannes Beeslaar, et al.
Vaccine|February 17, 2019
Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescentsTimo Vesikari, Lars Østergaard, Johannes Beeslaar, et al.
Vaccine|February 16, 2017
Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from FranceMuhamed-Kheir Taha, Julio Cesar Hawkins, Paul Liberator, et al.
Clinical and Vaccine Immunology : CVI|April 30, 2010
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlersSusanna Esposito, Susan Tansey, Allison Thompson, et al.
Infectious Diseases and Therapy|July 24, 2020
MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 StudiesJohannes Beeslaar, Judith Absalon, Annaliesa S Anderson, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2002
RFI-641, a potent respiratory syncytial virus inhibitorClayton C Huntley, William J Weiss, Anna Gazumyan, et al.
The Journal of Clinical Investigation|June 19, 2003
Heterologous immunity provides a potent barrier to transplantation toleranceAndrew B Adams, Matthew A Williams, Thomas R Jones, et al.
The Lancet. Infectious Diseases|October 18, 2016
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trialHelen S Marshall, Peter C Richmond, Johannes Beeslaar, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2004
Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survivalAndrew B Adams, Nozomu Shirasugi, Thomas R Jones, et al.
The Lancet. Infectious Diseases|May 10, 2012
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trialPeter C Richmond, Helen S Marshall, Michael D Nissen, et al.
Pageof 7